Children whose immune systems are compromised by cancer treatment, organ transplantation, or biologic therapies occupy a precarious position in respiratory virus season — and current vaccination practices may be failing them in ways that have gone underexamined. The convergence of rising immunocompromised pediatric populations and declining community vaccination rates creates compounding risk that this clinical review from Pediatrics brings into sharp focus.
The review addresses vaccination against three major respiratory pathogens — influenza, SARS-CoV-2, and RSV — in children whose immunological defenses are already compromised by hematopoietic cell transplants, solid organ transplants, chemotherapy, or biologic immunomodulators. A central problem identified is that most current vaccination recommendations for this population are extrapolated from data on healthy children or immunocompromised adults, because direct efficacy and immunogenicity data in immunocompromised pediatric patients remain sparse. Hospitalization rates, ICU admissions, and mortality in this group exceed those of immunologically intact children, driven by immature immune memory, absent pre-existing immunity, and elevated environmental exposure. Critically, the review highlights suboptimal vaccination rates not only in affected children but also in household contacts — a key cocooning layer of protection.
This is primarily a clinical guidance synthesis rather than a primary data study, which limits its ability to generate new causal evidence. What it does accomplish is consolidating a fragmented evidence base for practitioners navigating a genuinely difficult immunological problem: how to protect children whose immune response to vaccines may itself be blunted. Broader pediatric immunology research increasingly recognizes that transplant timing, lymphocyte reconstitution, and the specific biologic agent in use all materially affect vaccine immunogenicity. This review's framing of household contacts as a shared clinical responsibility — not an afterthought — reflects a population-health logic that primary care practitioners would do well to internalize. Given expanding indications for biologic therapies in pediatric autoimmune disease, the immunocompromised pediatric population is likely to grow, making this guidance increasingly relevant.